BE0003739530 - Common Stock

**UCB** gets a fundamental rating of **3** out of 10. The analysis compared the fundamentals against 50 industry peers in the **Pharmaceuticals** industry. The financial health of **UCB** is average, but there are quite some concerns on its profitability. **UCB** is quite expensive at the moment. It does show a decent growth rate.

In the past year **UCB** was profitable.

In the past year **UCB** had a positive cash flow from operations.

In the past 5 years **UCB** always reported a positive cash flow from operatings.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 2.21% | ||

ROE | 3.82% | ||

ROIC | 3.17% |

ROA(3y)4.1%

ROA(5y)4.99%

ROE(3y)7.02%

ROE(5y)8.47%

ROIC(3y)5.56%

ROIC(5y)7.04%

In the last couple of years the **Operating Margin** of **UCB** has declined.

With a **Gross Margin** value of **67.50%**, **UCB** perfoms like the industry average, outperforming **52.17%** of the companies in the same industry.

In the last couple of years the **Gross Margin** of **UCB** has declined.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 9.75% | ||

PM (TTM) | 6.53% | ||

GM | 67.5% |

OM growth 3Y-21.84%

OM growth 5Y-16.44%

PM growth 3Y-21.86%

PM growth 5Y-17.68%

GM growth 3Y-3.24%

GM growth 5Y-1.86%

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), **UCB** is destroying value.

Compared to 1 year ago, **UCB** has about the same amount of shares outstanding.

The debt/assets ratio for **UCB** is higher compared to a year ago.

An Altman-Z score of **3.53** indicates that **UCB** is not in any danger for bankruptcy at the moment.

The **Debt to Equity ratio** of **UCB** (**0.33**) is better than **63.04%** of its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.33 | ||

Debt/FCF | 6.83 | ||

Altman-Z | 3.53 |

ROIC/WACC0.44

WACC7.26%

A Current Ratio of **1.32** indicates that **UCB** should not have too much problems paying its short term obligations.

Looking at the **Current ratio**, with a value of **1.32**, **UCB** is in line with its industry, outperforming **50.00%** of the companies in the same industry.

A Quick Ratio of **0.92** indicates that **UCB** may have some problems paying its short term obligations.

The **Quick ratio** of **UCB** (**0.92**) is comparable to the rest of the industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.32 | ||

Quick Ratio | 0.92 |

The earnings per share for **UCB** have decreased by **-3.89%** in the last year.

The **Earnings Per Share** has been decreasing by **-2.58%** on average over the past years.

Looking at the last year, **UCB** shows a decrease in **Revenue**. The Revenue has decreased by **-4.80%** in the last year.

Measured over the past years, **UCB** shows a small growth in **Revenue**. The Revenue has been growing by **2.54%** on average per year.

EPS 1Y (TTM)-3.89%

EPS 3Y-7.81%

EPS 5Y-2.58%

EPS Q2Q%28.69%

Revenue 1Y (TTM)-4.8%

Revenue growth 3Y-0.6%

Revenue growth 5Y2.54%

Sales Q2Q%2.74%

The **Earnings Per Share** is expected to grow by **19.81%** on average over the next years. This is quite good.

The **Revenue** is expected to grow by **9.00%** on average over the next years. This is quite good.

EPS Next Y2.39%

EPS Next 2Y27.12%

EPS Next 3Y26.51%

EPS Next 5Y19.81%

Revenue Next Year8.8%

Revenue Next 2Y11.22%

Revenue Next 3Y11.01%

Revenue Next 5Y9%

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

The **Price/Earnings** ratio is **32.58**, which means the current valuation is very expensive for **UCB**.

The rest of the industry has a similar **Price/Earnings** ratio as **UCB**.

Compared to an average S&P500 **Price/Earnings** ratio of **28.57**, **UCB** is valued at the same level.

Based on the **Price/Forward Earnings** ratio of **31.82**, the valuation of **UCB** can be described as expensive.

Compared to the rest of the industry, the **Price/Forward Earnings** ratio of **UCB** is on the same level as its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 32.58 | ||

Fwd PE | 31.82 |

Based on the **Enterprise Value to EBITDA** ratio, **UCB** is valued a bit more expensive than the industry average as 60.87% of the companies are valued more cheaply.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 58.36 | ||

EV/EBITDA | 23.35 |

The high **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.

PEG (NY)13.64

PEG (5Y)N/A

EPS Next 2Y27.12%

EPS Next 3Y26.51%

With a yearly dividend of 0.70%, **UCB** is not a good candidate for dividend investing.

With a **Dividend Yield** of **0.70**, **UCB** pays less dividend than the S&P500 average, which is at **2.39**.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 0.7% |

The dividend of **UCB** has a limited annual growth rate of **2.45%**.

Dividend Growth(5Y)2.45%

Div Incr Years5

Div Non Decr Years5

The dividend of **UCB** is growing, but earnings are growing more, so the dividend growth is sustainable.

DP73.47%

EPS Next 2Y27.12%

EPS Next 3Y26.51%

**UCB SA**

EBR:UCB (6/20/2024, 7:00:00 PM)

**136.85**

**-2.2 (-1.58%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap25.97B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 0.7% |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 32.58 | ||

Fwd PE | 31.82 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)13.64

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 2.21% | ||

ROE | 3.82% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 9.75% | ||

PM (TTM) | 6.53% | ||

GM | 67.5% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.34

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.33 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1.32 | ||

Quick Ratio | 0.92 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-3.89%

EPS 3Y-7.81%

EPS 5Y

EPS Q2Q%

EPS Next Y2.39%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-4.8%

Revenue growth 3Y-0.6%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y